share_log

歌禮製藥-B：翌日披露報表

ASCLETIS-B: Next Day Disclosure Return

香港交易所 ·  Feb 9 00:34
Summary by Moomoo AI
歌禮製藥有限公司於2024年2月9日提交了翌日披露報表，披露了自2023年12月19日至2024年2月9日期間的股份購回活動。根據報表，公司在此期間共購回了67,100,000股普通股，佔已發行股份的6.1722%。最後一次購回發生在2024年2月9日，當日購回344,000股，每股價格介於HKD 1.7至HKD 1.75之間，總計花費HKD 601,130。購回的股份並未註銷，使得截至2024年2月9日的結存股份數量維持在1,044,821,000股。該公司確認，所有購回活動均獲得董事會正式授權批准，並符合香港聯合交易所有限公司證券上市規則的相關規定。
歌禮製藥有限公司於2024年2月9日提交了翌日披露報表，披露了自2023年12月19日至2024年2月9日期間的股份購回活動。根據報表，公司在此期間共購回了67,100,000股普通股，佔已發行股份的6.1722%。最後一次購回發生在2024年2月9日，當日購回344,000股，每股價格介於HKD 1.7至HKD 1.75之間，總計花費HKD 601,130。購回的股份並未註銷，使得截至2024年2月9日的結存股份數量維持在1,044,821,000股。該公司確認，所有購回活動均獲得董事會正式授權批准，並符合香港聯合交易所有限公司證券上市規則的相關規定。
Song Pharmaceutical Co., Ltd. filed a Next Day Disclosure Report on February 9, 2024, disclosing its share repurchase activities for the period from December 19, 2023 to February 9, 2024. According to the report, the company repurchased a total of 67,100,000 shares of common stock during this period, representing 6.1722% of the issued shares. The last repurchase took place on 9 February 2024 and repurchased 344,000 shares at a price of between HKD 1.7 and HKD 1.75 per share at a total cost of HKD 601,130. The repurchased shares were not written off, leaving the number of outstanding shares as of February 9, 2024 at 1,044,821,000 shares. The Company confirms that all repurchases have been formally authorized by the Board of Directors and comply with the relevant provisions of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Song Pharmaceutical Co., Ltd. filed a Next Day Disclosure Report on February 9, 2024, disclosing its share repurchase activities for the period from December 19, 2023 to February 9, 2024. According to the report, the company repurchased a total of 67,100,000 shares of common stock during this period, representing 6.1722% of the issued shares. The last repurchase took place on 9 February 2024 and repurchased 344,000 shares at a price of between HKD 1.7 and HKD 1.75 per share at a total cost of HKD 601,130. The repurchased shares were not written off, leaving the number of outstanding shares as of February 9, 2024 at 1,044,821,000 shares. The Company confirms that all repurchases have been formally authorized by the Board of Directors and comply with the relevant provisions of the Securities Listing Rules of the Hong Kong Stock Exchange Limited.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more